The Expanding Anti-Obesity Drug Market is driven by growing obesity rates
The anti-obesity drug market comprises drugs that help in weight management and body fat reduction by decreasing appetite or increasing fullness. Some common anti-obesity drugs are Phentermine, Orlistat, liraglutide and lorcaserin. Phentermine works by decreasing appetite whereas Orlistat blocks fat absorption in the gut. Liraglutide and lorcaserin function by inducing a feeling of fullness. These drugs provide efficient weight loss solutions but must be taken along with exercise and a low-fat calorie controlled diet for long term effects.
The Global anti-obesity drug market is estimated to be valued at US$ 2928.39 Mn in 2024 and is expected to exhibit a CAGR of 7.9% over the forecast period between 2024 to 2031.
Key Takeaways
Key players operating in the anti-obesity drug market are ARJO, Etac AB, Medline Industries Inc., Guldmann Inc., Sunrise Medical Inc., Stryker Corporation, Winncare Group (Mangar Health), Joerns Healthcare Inc., Invacare Corporation, Baxter (Hill Rom Holding Inc.), Gainsborough Healthcare Group, and Savaria Corporation (Handicare Group AB), among others. With increasing obesity rates globally, the demand for anti-obesity drugs is growing steadily. From 2020 to 2025, overweight and obesity are projected to affect over 1.12 billion and diabetic adults respectively worldwide. This rising prevalence creates huge opportunities for players in the anti-obesity drug market to expand globally.
The growing prevalence of obesity due to unhealthy eating habits and sedentary lifestyle has been a major factor driving the demand for Anti-Obesity Drugs Market Size . From 1980 to 2015, the global obesity rates almost doubled with over 650 million adults now considered obese. In the US alone, the obesity rates have tripled over the past four decades. The increasing obese population suffers from serious health issues like heart disease, diabetes and certain cancers, pushing them to adopt weight management treatments like anti-obesity drugs.
The global anti-obesity drug market players are expanding their business presence into emerging markets of Asia and Latin America to capture new growth opportunities. With growing medical needs in developing countries, there lies a huge scope for penetration of anti-obesity drugs. Additionally, increasing awareness about health risks of obesity as well as growing disposable income levels make patients opt for branded and prescription anti-obesity drugs.
Get more insights on This Topic- Anti-Obesity Drugs Market
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian